Antibiotic drug research and development: Should it be funded through public-private partnerships to succeed?

BMJ (Online)

Volumn 344, Issue 7852, 2012, Pages

  Paccaud, Jean Pierre ^a  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); COMMERCIAL PHENOMENA; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; EDITORIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; INTERNATIONAL COOPERATION; INVESTMENT; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; UNITED STATES; HEALTH; HUMAN; NOTE; RESEARCH;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; RESEARCH; WORLD HEALTH;

EID: 84859712553     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e2591     Document Type: Editorial

References (4)

1. Laxminarayan R, Heymann DL. Challenges of drug resistance in the developing world. BMJ 2012;344:e1567.
2. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 23Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ 2012;344:e1782.
3. WHO. The evolving threat of antimicrobial resistance - options for action. 2012. www.who.int/patientsafety/implementation/amr/publication/en/index. html.
4. Ambrose PG. Antibiotic bill doesn't GAIN enough ground. Nat Med 2011; published online 7 July.